<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01393093</url>
  </required_header>
  <id_info>
    <org_study_id>TMU-CIH-IR-002</org_study_id>
    <nct_id>NCT01393093</nct_id>
  </id_info>
  <brief_title>Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas</brief_title>
  <acronym>TACE-KMG</acronym>
  <official_title>Clinical Trial of Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effects of Transcatheter Arterial
      Chemoembolization (TACE) with KMG microsphere in treating advance-stage Hepatocellular
      Carinoma(HCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicentre, random, controlled clinical trial of Transcatheter
      Arterial Chemoembolization (TACE)with KMG Microsphere Treating Advance-stage Hepatocellular
      Carinomas.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>3 years</time_frame>
    <description>Time to progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total survival</measure>
    <time_frame>3 year</time_frame>
    <description>total survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>remission rate</measure>
    <time_frame>3 years</time_frame>
    <description>remiision rate</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2840</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>TACE -oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE-KMG ( routine dose Chemo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE-KMG( low dose Chemo )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>embolization agent:KMG microsphere( 150-450µm,0.2-2g) with low dose Epirubicin （5-10mg/m2）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE-KMG(withou chemo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>embolization agent:KMG microsphere( 150-450µm,0.2-2g)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Chemoembolization</intervention_name>
    <description>Transcatheter Arterial Chemoembolization</description>
    <arm_group_label>TACE -oil</arm_group_label>
    <arm_group_label>TACE-KMG ( routine dose Chemo)</arm_group_label>
    <arm_group_label>TACE-KMG( low dose Chemo )</arm_group_label>
    <arm_group_label>TACE-KMG(withou chemo)</arm_group_label>
    <other_name>Transcatheter Arterial Chemoembolization，TACE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hepatocellular Carinomas with diagnosis of pathology or cytology or consistent with
             China 2001 guideline of Clinical Diagnosis Hepatocellular Carinomas

          2. clinical stage（The Barcelona Liver Clinic staging system,BCLC B and C)，or can not
             receive surgical intervention

          3. liver function:Child-Pugh A、B

          4. PST 0—1（Eastern Cooperative Oncology Group Performance Score ,ECOG）

          5. Lifespan≥6 months

          6. First time to receive treatment

          7. Can accept the follow up

          8. informed consent was gotten

          9. the number of lesion ≤ 5

        Exclusion Criteria:

          1. pregnant or lactation woman

          2. emotional disturbance

          3. serious heart ,lung disfunction or serious diabetes mellitus

          4. serious reactiveness infections;（exp:type B or C hepatitis）

          5. liver function :Child-Pugh Score C

          6. thrombocyte＜6×109/L

          7. diffuse HCC

          8. widespread metastasis

          9. serious atherosclerosis

         10. acquired immunodeficiency syndrome;AIDS

         11. thrombosis or thrombosis event in 6 months

         12. renal inadequacy who need hemodialysis or peritoneal dialysis

         13. with other tumors except basal cell carcinoma and carcinoma in situ of cervix

         14. serious alimentary tract hemorrhage in 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi Guo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tianjin Medical University Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhi Guo, MD</last_name>
    <phone>13920076145</phone>
    <email>cjr.guozhi@vip.163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haipeng Yu, MD</last_name>
    <phone>13352070835</phone>
    <email>jieruke@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi Guo, MD</last_name>
      <phone>13920076145</phone>
      <email>cjr.guozhi@vip.163.com</email>
    </contact>
    <contact_backup>
      <last_name>Haipeng Yu, MD</last_name>
      <phone>13352070835</phone>
      <email>jieruke@yahoo.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Wenge Xing, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.tjmuch.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2011</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>TACE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

